Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.57 |
| ▸ | BCR | P11274 | 4/20 | 0.57 |
| ▸ | BRAF | P15056 | 6/20 | 0.57 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | KIT | P10721 | 6/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | KIF5B | P33176 | 1/20 | 0.55 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449261 | 0.96 | KIT (0.58) | ABL1BCRBRAFEGFRKIT | |
| SCHEMBL24449287 | 0.93 | ABL1 (0.59) | ABL1BCRRETKIF5BCCDC6 | |
| SCHEMBL24449136 | 0.90 | ABL1 (0.51) | ABL1BCRBRAFEGFRKIT | |
| SCHEMBL24449140 | 0.90 | ABL1 (0.50) | ABL1BCRBRAFEGFRKIT | |
| SCHEMBL24449099 | 0.86 | ABL1 (0.55) | ABL1BCRBRAFEGFRKIT | |
| SCHEMBL24449097 | 0.84 | AXL (0.43) | ABL1BCRKITCSF1RRET | |
| SCHEMBL24449233 | 0.80 | FGFR4 (0.60) | ABL1BRAFEGFRKITCSF1R | |
| SCHEMBL24449137 | 0.80 | ABL1 (0.58) | ABL1BCRBRAFEGFRKIT | |
| SCHEMBL24449289 | 0.79 | ABL1 (0.59) | ABL1RETKIF5BCCDC6 | |
| SCHEMBL24449143 | 0.79 | ABL1 (0.61) | ABL1BCRRETKIF5BCCDC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | ABL1 4516/4885BCR 4845/4885BRAF 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.